Analysts’ Viewpoint
Emergence of the novel coronavirus (SARS-CoV-2) led to a global pandemic, which resulted in high demand for SARS treatment and vaccine development. Significant investment by governments in the development of SARS treatments and vaccines is driving the global severe acute respiratory syndrome treatment market.
Rise in prevalence of SARS is expected to augment the demand for effective treatments, thus creating lucrative opportunities for key market players. Furthermore, lack of FDA-approved treatments for SARS disease and high unmet medical needs associated with the disease are creating opportunities for players to develop new and innovative treatments.
Decline in number of COVID-19 cases, decrease in research & development funding, rise in distribution & access challenges, and shift in focus toward other health concerns are projected to restrain the market in the next few years.
Severe Acute Respiratory Syndrome (SARS) is a viral respiratory illness caused by the SARS coronavirus. There is no specific treatment for SARS; however, treatment typically involves supportive care to relieve symptoms and help the body fight the virus. This could include oxygen therapy, pain & fever management, and breathing support.
SARS treatment primarily includes medications, medical devices, and inpatient care services. Increase in incidence of SARS and rise in demand for effective treatments and supportive care are projected to bolster global severe acute respiratory syndrome market size.
However, the global outbreak of COVID-19 caused by a related coronavirus has overshadowed the market for SARS treatment. The COVID-19 pandemic led to significant investment in research & development of treatments and vaccines for the disease, as well as surge in demand for medical supplies and services related to the treatment of COVID-19.
Governments and private organizations across the world provided support for research & development and production of treatments for SARS. The World Health Organization (WHO) played a significant role in coordinating international efforts to control the spread of SARS and support research on its treatment. In 2003, the WHO established a global research network to accelerate the development of treatments and vaccines for SARS.
Private organizations, such as pharmaceutical companies, were also involved in the development of treatments for SARS. For instance, Gilead Sciences developed the antiviral drug remdesivir, which has been shown to be effective in reducing the time to recovery in patients with SARS-CoV-2 (COVID-19).
Governments have also provided funding for SARS research through grants and public-private partnerships. For instance, the U.S. National Institutes of Health (NIH) provided funding for several studies aimed at understanding SARS and developing treatments, and has supported the development of vaccines and antiviral medications.
Overall, support from government and private organizations has been critical in advancing the understanding of SARS and developing treatments to control its spread and improve patient outcomes.
Partnerships and collaborations among pharmaceutical companies, research institutions, and government agencies have played an important role in advancing the development and availability of SARS treatments. Partnerships between pharmaceutical companies and research institutions have led to the development of new antiviral drugs and vaccine candidates for SARS.
Government agencies have collaborated with pharmaceutical companies to support the clinical development of SARS treatments and ensure rapid approval and distribution. These partnerships have accelerated the development of effective treatments for SARS and improved patient outcomes.
In terms of drug class, the antibiotics segment held the largest global severe acute respiratory syndrome treatment market share in 2021. Demand for antibiotics for the treatment of SARS caused by SARS-CoV-2 has been limited during the COVID-19 pandemic, as antibiotics are not effective against viruses.
Supportive care and antiviral drugs, such as remdesivir and favipiravir, are the primary treatments for SARS-CoV-2. However, antibiotics could be recommended in some COVID-19 cases, where a secondary bacterial infection occurs.
Based on indication, the SARS-CoV-2 segment dominated the global severe acute respiratory syndrome treatment market in 2021. SARS-CoV-2 is a virus that causes COVID-19, a respiratory illness that has become a global pandemic. The COVID-19 pandemic has led to an increase in demand for treatments and vaccines to prevent and treat the disease.
Pharmaceutical companies and research institutions are focusing on developing treatments for SARS-CoV-2, including antiviral drugs, monoclonal antibodies, and vaccines.
In terms of distribution channel, the hospital pharmacies segment is expected to account for significant share of the global severe acute respiratory syndrome market during the forecast period. Majority of patients with SARS require hospitalization and treatment with antiviral medications, which are administered through intravenous (IV) infusion in a hospital setting.
Hospital pharmacies play a critical role in ensuring that patients receive appropriate medications, dosages, and administration methods. They also collaborate with healthcare providers to monitor patients' progress and adjust treatment plans as required.
Hospital pharmacies have access to a range of medications, including specialized therapeutics for lung diseases. These pharmacies are staffed with trained pharmacists who can provide expert advice on medication use and management. They also work closely with other healthcare professionals, such as doctors and nurses, which allows for better coordination of care and improved patient outcomes.
As per SARS treatment market report, North America dominated the global severe acute respiratory syndrome market in 2021. This can be ascribed to the increase in research & development efforts toward development of vaccines & antiviral medications to prevent SARS and measures to contain its spread. Management of SARS is primarily supportive, and includes measures such as providing oxygen, managing fever & other symptoms, and preventing secondary infections.
The market in North America is expected to be driven by the rise in research & development of new treatments and vaccines. However, it is likely to be influenced by the ongoing COVID-19 pandemic and availability of effective treatments and vaccines for both SARS and COVID-19.
Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by prominent manufacturers in the global severe acute respiratory syndrome treatment market. Regeneron Pharmaceuticals, Inc., Eli Lilly and Company, Merck, GSK, Gilead Sciences, Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Pfizer, Inc., CN Bio, AbbVie, and Swedish Orphan Biovitrum are the leading market players.
The severe acute respiratory syndrome treatment market report profiles key players based on parameters such as company overview, financial overview, strategies, portfolio, segments, and recent developments.
|
Attribute |
Detail |
|
Size in 2021 |
US$ 24.6 Bn |
|
Forecast (Value) in 2031 |
More than US$ 8.6 Bn |
|
Growth Rate (CAGR) |
-14.5% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2020 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global industry was valued at US$ 24.6 Bn in 2021.
It is projected to reach US$ 8.6 Bn by 2031.
The CAGR is anticipated to be -14.5% from 2022 to 2031.
Increase in SARS-CoV-2 (COVID-19) cases globally and support from government & private organizations for R&D and production of SARS treatments.
North America is projected to account for significant share during the forecast period.
Regeneron Pharmaceuticals, Inc., Eli Lilly and Company, Merck, GSK, Gilead Sciences, Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Pfizer, Inc., CN Bio, AbbVie, and Swedish Orphan Biovitrum.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global C Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Severe Acute Respiratory Syndrome Treatment Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Regulatory Scenario
5.3. Insights on Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective
5.4. COVID-19 Impact Analysis
6. Global Severe Acute Respiratory Syndrome Treatment Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017–2031
6.3.1. Antibiotics
6.3.2. Antivirals
6.3.3. Corticosteroids
6.3.4. Monoclonal Antibodies
6.3.5. Others
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Severe Acute Respiratory Syndrome Treatment Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Indication, 2017–2031
7.3.1. SARS-CoV
7.3.2. SARS-CoV-2
7.4. Market Attractiveness Analysis, by Indication
8. Global Severe Acute Respiratory Syndrome Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Others
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Severe Acute Respiratory Syndrome Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Severe Acute Respiratory Syndrome Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017–2031
10.2.1. Antibiotics
10.2.2. Antivirals
10.2.3. Corticosteroids
10.2.4. Monoclonal Antibodies
10.2.5. Others
10.3. Market Value Forecast, by Indication, 2017–2031
10.3.1. SARS-CoV
10.3.2. SARS-CoV-2
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Indication
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Severe Acute Respiratory Syndrome Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017–2031
11.2.1. Antibiotics
11.2.2. Antivirals
11.2.3. Corticosteroids
11.2.4. Monoclonal Antibodies
11.2.5. Others
11.3. Market Value Forecast, by Indication, 2017–2031
11.3.1. SARS-CoV
11.3.2. SARS-CoV-2
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Indication
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2031
12.2.1. Antibiotics
12.2.2. Antivirals
12.2.3. Corticosteroids
12.2.4. Monoclonal Antibodies
12.2.5. Others
12.3. Market Value Forecast, by Indication, 2017–2031
12.3.1. SARS-CoV
12.3.2. SARS-CoV-2
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Indication
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Severe Acute Respiratory Syndrome Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017–2031
13.2.1. Antibiotics
13.2.2. Antivirals
13.2.3. Corticosteroids
13.2.4. Monoclonal Antibodies
13.2.5. Others
13.3. Market Value Forecast, by Indication, 2017–2031
13.3.1. SARS-CoV
13.3.2. SARS-CoV-2
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Indication
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017–2031
14.2.1. Antibiotics
14.2.2. Antivirals
14.2.3. Corticosteroids
14.2.4. Monoclonal Antibodies
14.2.5. Others
14.3. Market Value Forecast, by Indication, 2017–2031
14.3.1. SARS-CoV
14.3.2. SARS-CoV-2
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Indication
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company (2021)
15.3. Company Profiles
15.3.1. Regeneron Pharmaceuticals, Inc.
15.3.1.1. Company Overview
15.3.1.2. Drug Class Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Merck
15.3.2.1. Company Overview
15.3.2.2. Drug Class Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. GSK
15.3.3.1. Company Overview
15.3.3.2. Drug Class Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Gilead Sciences, Inc.
15.3.4.1. Company Overview
15.3.4.2. Drug Class Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. AstraZeneca plc
15.3.5.1. Company Overview
15.3.5.2. Drug Class Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. F. Hoffman La Roche
15.3.6.1. Company Overview
15.3.6.2. Drug Class Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Pfizer
15.3.7.1. Company Overview
15.3.7.2. Drug Class Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Eli Lilly and Company
15.3.8.1. Company Overview
15.3.8.2. Drug Class Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Swedish Orphan Biovitrum
15.3.9.1. Company Overview
15.3.9.2. Drug Class Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. CN Bio
15.3.10.1. Company Overview
15.3.10.2. Drug Class Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. AbbVie
15.3.11.1. Company Overview
15.3.11.2. Drug Class Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
List of Tables
Table 01: Global Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 02: Global Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 03: Global Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 07: North America Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 08: North America Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 11: Europe Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 12: Europe Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 15: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 16: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: Latin America Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 19: Latin America Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 20: Latin America Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 23: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 24: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) and Distribution (%), by Region, 2017 and 2031
Figure 02: Global Severe Acute Respiratory Syndrome Treatment Market Revenue (US$ Mn), by Drug Class, 2021
Figure 03: Global Severe Acute Respiratory Syndrome Treatment Market Value Share, by Drug Class, 2021
Figure 04: Global Severe Acute Respiratory Syndrome Treatment Market Revenue (US$ Mn), by Indication, 2021
Figure 05: Global Severe Acute Respiratory Syndrome Treatment Market Value Share, by Indication, 2021
Figure 06: Global Severe Acute Respiratory Syndrome Treatment Market Revenue (US$ Mn), by Distribution Channel, 2021
Figure 07: Global Severe Acute Respiratory Syndrome Treatment Market Value Share, by Distribution Channel, 2021
Figure 08: Global Severe Acute Respiratory Syndrome Treatment Market Value Share, by Region, 2021
Figure 09: Global Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 10: Global Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Drug Class, 2017 and 2031
Figure 11: Global Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
Figure 12: Global Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Indication, 2017 and 2031
Figure 13: Global Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Indication, 2022-2031
Figure 14: Global Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 15: Global Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 16: Global Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Region, 2017 and 2031
Figure 17: Global Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Region, 2022-2031
Figure 18: North America Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 19: North America Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Country, 2017–2031
Figure 20: North America Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Country, 2017 and 2031
Figure 21: North America Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Drug Class, 2017 and 2031
Figure 22: North America Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Indication, 2017 and 2031
Figure 23: North America Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 24: North America Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 25: North America Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Indication, 2022–2031
Figure 26:North America Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 27: Europe Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 28: Europe Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 29: Europe Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 30: Europe Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Drug Class, 2017 and 2031
Figure 31: Europe Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Indication, 2017 and 2031
Figure 32: Europe Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 33: Europe Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 34: Europe Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Indication, 2022–2031
Figure 35: Europe Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 36: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 37: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 38: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 39: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Drug Class, 2017 and 2031
Figure 40: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Indication, 2017 and 2031
Figure 41: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 42: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 43: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Indication, 2022–2031
Figure 44: Asia Pacific Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 45: Latin America Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 46: Latin America Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 47: Latin America Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 48: Latin America Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Drug Class, 2017 and 2031
Figure 49: Latin America Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Indication, 2017 and 2031
Figure 50: Latin America Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 51: Latin America Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 52: Latin America Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Indication, 2022–2031
Figure 53: Latin America Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 54: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 55: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 56: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 57: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Drug Class, 2017 and 2031
Figure 58: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Indication, 2017 and 2031
Figure 59: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 60: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031
Figure 61: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Indication, 2022–2031
Figure 62: Middle East & Africa Severe Acute Respiratory Syndrome Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Severe Acute Respiratory Syndrome Treatment Market
